Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

2.490 +0.010 (+0.40%)
Streaming Delayed Price Updated: 12:59 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lisata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ
From Virtual Investor Conferences
Via GlobeNewswire
Recap: Lisata Therapeutics Q4 Earnings
 
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics's Earnings Outlook
 
Via Benzinga
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Present at BIO CEO & Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Earnings Preview: Lisata Therapeutics
 
Via Benzinga
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic gastroesophageal adenocarcinoma 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Present at NobleCon19 Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors... 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in October
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Participation in InfoSec World 2023
Gregory Berkin, Chief Information Officer of Lisata, to participate in keynote discussion on CISO leadership and managing the risks of artificial intelligence 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
Independent Data Safety Monitoring Committee recommends study continuation (criteria for futility not met) 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in September
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.